18983288589(微信同号)
18983288589(微信同号)
18908392210(微信同号)
18980413049
ChiCTR1800017905
正在进行
/
/
/
2018-08-20
/
/
Carpal Tunnel Syndrome
COMPARISON OF EFFECTIVENESS OF MEDIAN NERVE NEURODYNAMIC MOBILIZATION VERSUS CARPAL BONE MOBILIZATION ON PAIN, SYMPTOM SEVERITY AND FUNCTIONAL STATUS IN CARPAL TUNNEL SYNDROME
COMPARISON OF EFFECTIVENESS OF MEDIAN NERVE NEURODYNAMIC MOBILIZATION VERSUS CARPAL BONE MOBILIZATION ON PAIN, SYMPTOM SEVERITY AND FUNCTIONAL STATUS IN CARPAL TUNNEL SYNDROME
54000
To determine the effectiveness of median nerve mobilization vs. carpal bone mobilization in reducing pain & symptom severity and improving functional status in subjects with carpal tunnel syndrome
随机平行对照
Ⅰ期
The patients will be asked to choose a token from the a box on which group of patient will be mentioned. Box will be filled with equal number of tokens for both groups to ensure equal sample size. None of the patients will be aware of the subgroup they will have
/
Self Financed
/
30
/
2018-08-01
2018-11-30
/
1. Age 25-55 years. 2. Both male and female patients diagnosed with CTS; 3. Patients with positive phalen's test, positive tinel's test and positive upper limb tension test for median nerve; 4. Patient's having median nerve latencies above 4ms.;
登录查看1. Any red flags (tumor, fracture, metabolic diseases, rheumatoid arthritis, osteoporosis,HTN, prolonged history of steroid use, etc); 2. Patients with double crush syndrome, cervical or thoracic origin of symptoms, scaphoid instability, shoulder injuries, recent fractures and crush injuries, hypermobile joints, pregnancy and women undergoing hormone replacement therapy; 3. Evidence of central nervous system involvement; 4. Patients who requested to leave the study and history of other treatments including local corticosteroid and using of physical modalities and physiotherapy injection and splint in 3 months ago; 5. Any sensory and/or motor deficit in either ulnar or radial nerve.;
登录查看Riphah International University, Pakistan
5400
约印创投2025-01-16
求实药社2025-01-16
Genhouse2025-01-16
IPHASE2025-01-16
动脉网2025-01-16
动脉网-最新2025-01-16
药明康德2025-01-16
药明康德2025-01-16
再鼎医药2025-01-16
Rimonci2025-01-15